Literature DB >> 28044946

Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.

Gregory W Mattingly1, Richard H Anderson2.   

Abstract

Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment options to individualize treatment for our patients. This article will: ∙ review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic remission throughout the day ∙ summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and ∙ discuss the various pharmacologic treatment options with a focus on recently developed molecules and novel delivery systems.

Entities:  

Keywords:  ADHD; attention deficit/hyperactivity disorder; pharmacology; rating scales; review

Mesh：

Substances：

Year:  2016        PMID： 28044946     DOI： 10.1017/S1092852916000808

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  4 in total

1.  Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.

Authors:  M Janelle Cambron-Mellott; Jaromir Mikl; Joana E Matos; Jennifer G Erensen; Kathleen Beusterien; Marc J Cataldo; Bernadette Hallissey; Gregory W Mattingly
Journal:  Patient Prefer Adherence       Date:  2021-05-21       Impact factor: 2.711

2.  The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.

Authors:  Azmi Nasser; Joseph T Hull; Tesfaye Liranso; Gregory D Busse; Zare Melyan; Ann C Childress; Frank A Lopez; Jonathan Rubin
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-03       Impact factor: 2.570

3.  A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.

Authors:  Azmi Nasser; Tesfaye Liranso; Toyin Adewole; Nicholas Fry; Joseph T Hull; Gregory D Busse; Fatima Chowdhry; Andrew J Cutler; Nandita Joshi Jones; Robert L Findling; Stefan Schwabe
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

4.  Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults.

Authors:  Martin A Katzman; Greg Mattingly; Larry J Klassen; Marc J Cataldo; Graeme A E Donnelly
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.